Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients.
BTLA
Co-inhibitors
Cytomegalovirus
Lung transplant
PD-1
T-cells
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
10
07
2019
revised:
04
09
2019
accepted:
05
09
2019
pubmed:
10
9
2019
medline:
20
5
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
Cytomegalovirus infection (CMVi) occurs frequently in transplant patients. Co-inhibitory molecules on CMV-specific T-cells (TCMV) in patients after lung transplantation were investigated. 59 lung transplant patients were stratified according to anti-CMV serostatus at time of transplantation. The co-inhibitors Programmed-Death-Receptor-1 (PD1) and B-and-T-Lymphocyte-Attenuator (BTLA) were detected on TCMV by flow cytometry (FACS). TCMV were detectable in CMV sero-positive patients (R+) and in CMV sero-negative patients with a lung graft of a CMV sero-positive donor (D+/R-); in both cases, the frequency of TCMV was higher than in healthy controls (HC). PD-1 on TCMV was increased in D+/R+ and D+/R- patients as compared to HC. BTLA was significantly enhanced on TCMV of D+/R- patients vs. HC. R+ patients with CMV reactivation in the past had an increased fraction of BTLA+ TCMV. In conclusion, the expression pattern of co-inhibitory molecules on TCMV is altered in patients after lung transplantation.
Identifiants
pubmed: 31499181
pii: S1521-6616(19)30359-6
doi: 10.1016/j.clim.2019.108258
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
BTLA protein, human
0
CD274 protein, human
0
Receptors, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108258Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.